Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Erenumab is not associated with significant reductions in weekly attacks in patients with chronic cluster headache vs placebo ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Long-term follow-up data show that the preventive effects of short-term treatment with abatacept disappear after 4-5 years.

Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Patients with bronchiectasis and a Pseudomonas aeruginosa infection receiving gremubamab, a bispecific monoclonal antibody, ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...